Cynomolgus B2M / Beta-2-microglobulin Protein (His Tag)

Beta-2-microglobulin Protein Datasheet

B2M / Beta-2-microglobulin Protein Product Information

• Synonym: B2M
• Protein Construction: A DNA sequence encoding the Cynomolgus B2M (Q6V7J5) (Met 1- Met119) was expressed, fused with a polyhistidine tag at the C-terminus.
• Source: Cynomolgus
• Expression Host: Human Cells

B2M / Beta-2-microglobulin Protein QC Testing

• Purity: > 96 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ile 21
• Molecular Mass: The recombinant heterodimer of Cynomolgus B2M comprises 110 amino acids and has a calculated molecular mass of 13.1 KDa. The apparent molecular mass of cyno B2M heterodimer is approximately 14 KDa respectively in SDS-PAGE.
• Formulation: Lyophilized from sterile PBS, pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: B2M / Beta-2-microglobulin protein

B2M / Beta-2-microglobulin Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

B2M / Beta-2-microglobulin Protein Description

Beta-2-microglobulin, also known as B2M, is a secreted protein which belongs to thebeta-2-microglobulin family. It contains oneIg-like C1-type (immunoglobulin-like) domain. Beta-2 microglobulin (B2M) plays a pivotal role in the biology of mammals, including its association with major histocompatibility complex (MHC) Class I gene products. The latter molecules have been shown to affect reproduction in both mice and humans. B2M forms the small invariable light chain subunit of class I HLA antigens on the cell membrane of all nucleated cells. During the continuous turnover of the HLA molecules. B2M is shed from the cell membrane into blood. Lymphocytes are the main source of serum free B2M. Serum B2M concentration is increased in renal diseases, various malignant diseases and some inflammatory and autoimmune disorders. In lymphatic malignancies serum B2M has significant prognostic value. B2M has been shown as a marker for monitoring inflammatory disease activity and it appears likely to have a destructive role in amyloidosis-related arthritis. B2M might be involved in the OA (osteoarthritis) pathogenesis. Defects in B2M are the cause of hypercatabolic hypoproteinemia. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation. B2M could be a potential therapeutic target in ovarian cancer.

References

1. Miyata T. et al.,1994 Biochemistry. 33: 12215-21.
2. Remes,K. et al.,1996, Leuk Lymphoma. 21 (3-4): 233-8.
3. Trinh CH. et al., 2002, Proc Natl Acad Sci. 99: 9771-6.
4. He XH. et al., 2004, Sheng Wu Gong Cheng Xue Bao. 20: 99-103.
5. Kihara M. et al., 2006, J Biol Chem. 281: 31061-9.
6. Ricagno S. et al., 2009, Biochem Biophys Res Commun. 380: 543-7.